secwatch.observer — SEC 8-K summary
======================================

Issuer:     Q32 Bio Inc. (QTTB)
CIK:        0001661998
Form:       8-K/A
Filed at:   2024-03-22T23:59:59+00:00
Accession:  0001193125-24-074775
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Homology Medicines: reverse stock split effective March 26; Nasdaq listing approved for combined company
--------------------------------------------------------------------------------

- Reverse stock split at 1-for-18 ratio effective at trading open on March 26, 2024; new CUSIP 746964105.
- Stockholders to receive cash for fractional shares based on March 25 closing price.
- Nasdaq Staff approved initial listing application for continued listing of Homology common stock post-merger with Q32.
- Reverse split is part of the merger with Q32 Bio Inc.; Q32 will survive as a wholly owned subsidiary.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1661998/000119312524074775/0001193125-24-074775-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1661998/000119312524074775/d817398d8ka.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-074775

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer